Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
STOCKHOLM, Jan. 25, 2026 /PRNewswire/ — BioArctic AB’s (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics…
